Published in final edited form as:

Environ Toxicol Pharmacol. 2007 March ; 23(2): 179–184.

Inhibition of DAT function attenuates manganese accumulation in the globus pallidus

Joel G. Anderson, Paula T. Cooney, and Keith M. Erikson*

Department of Nutrition, The University of North Carolina at Greensboro, Greensboro, NC 27402

Abstract

Manganese (Mn) is an essential nutrient, though exposure to high concentrations may result in neurotoxicity characterized by alterations in dopamine neurobiology. To date, it remains elusive how and why Mn targets dopaminergic neurons although recently the role of the dopamine transporter has been suggested. Our primary goal of this study was to examine the potential roles of the monoamine transporters, dopamine transporter (DAT), serotonin transporter (SERT) and norepinephrine transporter (NET), in neuronal Mn transport. Using striatal synaptosomes, we found that only inhibition of DAT significantly decreased Mn accumulation. Furthermore, weanling rats chronically exposed to Mn, significantly accumulated Mn in several brain regions. However, rats receiving the specific DAT inhibitor GBR12909 (1 mg/kg bw, three times/week; four weeks) had significantly lower Mn levels only in the globus pallidus compared to saline-treated rats ($p < 0.05$). Our data show that inhibition of DAT exclusively inhibits Mn accumulation in the globus pallidus during chronic exposure.

Keywords

Dopamine transporter; Manganese; Rat; Neurotoxicity

Introduction

Manganese (Mn) is an essential nutrient and functions as a critical cofactor for many key enzymes involved in cellular processes (Hurley and Keen, 1987). It is required for proper immune function, regulation of metabolism, reproduction, digestion, and bone growth (Aschner et al., 2005). However, exposure to high concentrations of Mn is known to result in neurotoxicity. Mn neurotoxicity, or manganism, shares neuropathologies with several clinical disorders, in particular Parkinson's disease (Pal et al., 1999; Aschner et al., 2005). Manganism is characterized by the accumulation of Mn in iron-rich, dopaminergic brain regions, specifically the basal ganglia (Aschner et al., 2005). The globus pallidus within the basal ganglia is a target region for Mn accumulation during Mn toxicity (Verity, 1999; Erikson et al., 2002; 2004).

Most research in the area of Mn neurotoxicity has focused on its effect on metabolism of dopamine. Why and by what means Mn specifically accumulates in brain regions rich in dopamine remains unclear. The neurotoxins 1-methyl-4-phenylpyridium (MPP+) and paraquat

* Corresponding Author: 318 Stone Building, UNCG, POB 26170, Greensboro, NC 27402-6170; Phone: 336-256-0327; Fax: 336-334-4129; email: kmerikso@uncg.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

are known to be selectively lethal to dopaminergic neurons due to the fact that they are transported by the dopamine transporter (DAT) (Petzinger et al., 2006; Yang and Tiffany-Castiglioni, 2005). Ingersoll et al. (1999) examined the effect on Mn uptake by inhibiting DAT. Cocaine, a DAT inhibitor, and reserpine, which decreases extracellular dopamine concentrations by inhibiting vesicular reuptake in the synapse, were administered to rats injected with Mn intrathecally. A significant decrease in Mn accumulation in the ventral pallidum was seen in rats treated with both. This suggests a potential role for the DAT and dopamine metabolism in the transport of Mn. However, both cocaine and reserpine are known to affect other neurotransmitters, most notably serotonin and norepinephrine (Ritz et al., 1990). Therefore, it is unclear if this decrease in ventral pallidum Mn concentrations is directly related to the DAT being inhibited or is related to the inhibition of the serotonin transporter and/or the norepinephrine transporter.

A recent study by this lab (Erikson et al., 2005) examined the potential role of the DAT in Mn accumulation in the brain using a knockout mouse model. Homozygous DAT-KO and WT mice were exposed to an acute dose of 50 mg/kg of MnCl₂ via intraperitoneal injection. After fifteen minutes, brains were removed for metal analysis. No difference in basal Mn levels was seen between the DAT-KO mice and the WT mice. However, there was a significant 40% decrease in Mn accumulation in the striatum of the DAT-KO mice receiving Mn injection compared to the WT mice receiving Mn injection. This suggests that the DAT may not play a central role in normal Mn transport in the brain, but may become relevant in a toxicological paradigm in terms of Mn exposure.

While the effect of Mn toxicity on dopamine metabolism has been the primary focus, the effect of Mn toxicity on the metabolism of the biogenic amines norepinephrine (NE) and serotonin (5-HT) has not been as extensively studied. One group exposed PC12 cells to Mn pyrophosphate which resulted in more than a 70% decrease in cellular serotonin levels (Reaney and Smith, 2005). Another lab found an increase in norepinephrine in the brain stem of rats treated with MnCl₂, but norepinephrine concentrations were decreased in the hippocampus (Autissier et al., 1982). While the effect of Mn exposure on NE and 5-HT concentrations has been examined, the role(s) of the NET and SERT during Mn toxicity is virtually unknown.

The goal of the present study was to examine the potential role of the biogenic amine transporters DAT, NET, and SERT in Mn accumulation in the male rat brain. Due to the homology in the amino acid sequence of these transporters, their sodium dependence of their uptake mechanisms, and the fact that how and where Mn interacts with these proteins is unknown (Borowsky and Hoffman, 1995), striatal synaptosomes were utilized to screen for potential effects of inhibiting these biogenic amine transporters on Mn accumulation in the striatum, a target region for Mn neurotoxicity. The results of these experiments lead to in vivo studies using both dietary and pharmacological intervention to examine the effects on Mn accumulation on the developing male rat brain.

Materials and Methods

Animals

Weanling male Sprague-Dawley rats were obtained from Harlan (Indianapolis, IN) and maintained on a modified AIN-93-G diet (BioServ, Frenchtown, NJ) containing 35 mg/kg Fe and 10 mg/kg Mn. Rats had free access to food and water and were housed in hanging cages in the animal facility in a typical light: dark cycle (0600–1800 light on) with a room temperature of 25° C. Animal care was in accordance with the University of North Carolina at Greensboro Animal Care and Use Committee.

Synaptosome isolation

The striata from the brains of control rats were removed and synaptosomes were obtained from this region. The brain regions were homogenized using a Teflon/glass homogenizer in 20 volumes of ice cold 0.32 M sucrose-HEPES, pH 7.4. The homogenate was then centrifuged at 2000 x g for 10 minutes at 4° C. The supernatant was removed and centrifuged at 20,000 x g for 15 minutes at 4° C. The pellet was resuspended in 10 ml fresh ice cold Krebs-Ringer-HEPES (KRH) buffer [118.4 mM NaCl, 1.18 mM MgSO₄, 4.7 mM KCl, 1.2 mM KH₂PO₄, 10.0 mM HEPES, 5.6 mM dextrose (pH 7.4)] containing 10 µM pargyline (Sigma, St. Louis, MO). An aliquot of 200 µl of the synaptosomes was placed in a tube with 50 µl KRH buffer.

In vitro studies

Using striatal synaptosomes, we examined the effect of inhibiting three biogenic amine transporters on Mn transport. We used GBR12909 ($K_i = 1$ nM), desipramine ($K_i = 3.2$ µM), and fluoxetine ($K_i = 0.6$ µM) to block DAT, NET, and SERT, respectively. All drugs were purchased from Sigma (St. Louis, MO).

To establish an appropriate working concentration for each of the transporter inhibitors, dose response experiments were conducted using ³H-dopamine, ³H-norepinephrine, and ³H-serotonin. A 200 µl aliquot of synaptosomes was incubated either in the presence or absence of a biogenic amine transporter inhibitor at various concentrations (0.1 µM to 100 µM) for 5 minutes at 37° C in a water bath. A 10 µl aliquot of the respective tritiated neurotransmitter (50 nM) (NEN, Boston, MA) was added to each tube and tubes were incubated for 15 minutes at 37° C. The reaction was stopped by adding ice cold KRH buffer to each tube followed by rapid filtration through a GF/F Whatman fiberglass filter on a Millipore sampling manifold. Filters were washed twice with ice cold KRH, placed in scintillation vials with 5 ml scintillation cocktail, and counted on a Beckman LS scintillation counter (Beckman, Fullerton, CA). An additional set of tubes, one for each treatment group, was incubated on ice to determine non-specific uptake.

To assess Mn concentration in the striatal synaptosomes, a 200 µl aliquot of synaptosomes was incubated with or without 500 µM MnCl₂ in the presence or absence of each of the biogenic amine transporter inhibitors at the ED₅₀ dose (1 µM GBR12909; 10 µM fluoxetine; 10 µM desipramine) for 15 minutes at 37° C in a water bath. The reaction was stopped by adding ice cold KRH buffer to each tube followed by rapid filtration through a GF/F Whatman fiberglass filter on a Millipore sampling manifold. After filtration, the filters were digested in 500 µl ultra-pure nitric acid for 48 hours. The supernatant was removed and Mn concentration was determined by GFAAS.

Iron and manganese analysis

Tissue Mn and iron (Fe) concentrations were measured with graphite furnace atomic absorption spectroscopy (GFAAS) (Varian AA240, Varian, Inc USA). Tissue was digested in ultra pure nitric acid (1:10 w/v dilution) for 48–72 hours in a sandbath (60° C). An aliquot of 100 µl of digested tissue was brought to 1 ml total volume with 2% nitric acid and analyzed for Mn and Fe as outlined previously (Erikson and Aschner, 2006).

In vivo studies

Because synaptosomal studies showed a direct interaction between DAT and Mn accumulation, we sought to examine the effect of DAT blockade *in vivo*. Weanling male Sprague-Dawley rats ($n = 24$) (Harlan, Indianapolis, IN) were randomly placed into one of four dietary treatment groups: control (CN), iron-deficient (ID), control with Mn supplementation (via the drinking water; 1g Mn/L) (CNMn), and ID with Mn supplementation (IDMn) (Figure 1). The CN diet

consisted of a modified AIN-93-G diet (BioServ, Frenchtown, NJ) containing 35 mg/kg Fe and 10 mg/kg Mn. The ID diet consisted of a modified AIN-93-G diet (BioServ, Frenchtown, NJ) containing 6 mg/kg Fe and 10 mg/kg Mn. Two independent experiments with two separate sets of animals were conducted ($n = 24$ for each experiment). Within each dietary group, half of the rats received intraperitoneal injections of GBR12909 (Sigma, St. Louis, MO), 1 mg/kg (ED-50), three times per week while the other half received saline injections of equal volume. Dietary and pharmacological intervention lasted for four weeks. Brains were dissected into five regions, known for accumulating Mn to varying degrees: caudate putamen (CP), globus pallidus (GP), hippocampus (HC), substantia nigra (SN), and cerebellum (CB).

Statistical analysis

The data were analyzed using the SPSS v13, statistical analysis package (SPSS, Inc. Chicago, IL). Multiple factor analysis of variance was used to test for between subject effects (level of Fe, level of Mn, and drug treatment). When the overall significance resulted in rejection of the null hypothesis ($p < 0.05$), Dunnett's procedure was used to evaluate treatment means compared to control means.

Results

Synaptosomal uptake of Mn

To screen for biogenic amine transporters with a potential role in Mn accumulation, striatal synaptosomes were utilized. To establish a working concentration for each of the transporter inhibitors, striatal synaptosomes were treated with various concentrations (0.1–100 μ M) of the individual inhibitors before being incubated with the respective tritiated neurotransmitter. Treatment with all three drugs significantly inhibited the uptake of the respective tritiated neurotransmitter in striatal synaptosomes at the ED50 dose ($p < 0.05$) (Figure 2).

To examine the effect of each of the inhibitors on Mn accumulation, synaptosomes were incubated with MnCl_2 in the presence of each of the inhibitors (1 μ M GBR; 10 μ M fluoxetine; 100 μ M desipramine). Only treatment with GBR12909 significantly decreased accumulation of Mn compared to synaptosomes not treated with GBR12909 ($p < 0.001$) (Figure 3). No significant difference was seen in the amount of Mn accumulation in those samples treated with either desipramine or fluoxetine in the presence of Mn compared to those samples without Mn treatment (Figure 3). Unexpectedly, a significant increase in Mn accumulation was seen in synaptosomes treated with GBR12909 in which Mn was not added ($p < 0.05$) (Figure 3).

In vivo studies

Body weight and hematocrit—Rats receiving the CN diet gained significantly more weight than rats receiving the ID diet ($p < 0.05$) and hematocrit was significantly lower in rats receiving the ID diet compared to the CN diet ($p < 0.05$) indicating that iron deficiency anemia had been induced. Treatment with GBR12909 had no effect on body weight or hematocrit levels versus those animals receiving saline injections (Table 1).

Manganese—Mn concentrations were significantly higher in supplemented groups versus non-supplemented groups in most brain regions ($p < 0.05$) (Figure 4). Treatment with GBR12909 significantly decreased accumulation of Mn in the GP of supplemented rats ($p < 0.001$) and there was a trend toward significance in the HC of CN rats ($p = 0.07$) (Figure 5).

Iron—Overall Fe concentrations were significantly different between CN and ID groups ($p < 0.05$); however, Fe concentrations were not statistically lower in ID groups versus CN

groups within individual brain regions (Figure 6). Treatment with GBR12909 had no effect on Fe accumulation in the brain.

Discussion

In this study, both *in vitro* and *in vivo* data suggest a potential role for the DAT in the transport of Mn into the globus pallidus during toxic exposure. Initially, striatal synaptosomes were utilized to screen three biogenic amine transporters as potential Mn transporters: DAT, NET, and SERT. Previously, the DAT had implicated as a putative Mn transporter (Ingersoll et al., 1999). However, the potential role of other monoamine transporters in the striatum in Mn transport, specifically norepinephrine and serotonin, remained elusive. Furthermore, this previous study administered Mn directly into the central nervous system bypassing any systemic or blood brain barrier mechanisms involved in Mn intoxication. Therefore we sought to study the role(s) of biogenic amine transporters in brain Mn accumulation due to chronic, dietary exposure.

Before we launched into the animal intensive studies, we evaluated the efficacy of specific uptake inhibitors for DAT, NET and SERT on blocking Mn transport into striatal synaptosomes. Synaptosomes were used because of their relative simplicity and their proven sensitivity to manipulation of neurotransmitter uptake. Dissociation from other interacting neuronal systems is advantageous in this case in order to provide direct interpretation of results and allow us to plan the dietary studies in a precise fashion.

Synaptosomes were isolated from the striatum, as Mn is known to accumulate in the Fe and dopamine-rich regions of the basal ganglia (Aschner et al. 2005). GBR12909 was used to specifically inhibit DAT; desipramine was used to inhibit NET, and fluoxetine to inhibit SERT (Figure 2). Only those synaptosomes treated with the specific DAT inhibitor, GBR12909, significantly blocked Mn accumulation *in vitro* (Figure 3). No effect was seen in those synaptosomes treated with either desipramine or fluoxetine. These data suggest that DAT is involved in Mn accumulation in the striatum during toxic exposure and agree with findings from previous studies (Ingersoll et al., 1999; Erikson et al., 2005). In addition, these *in vitro* observations suggest NET and SERT are not involved in Mn transport during toxicity in the striatum. For the purposes of this study the striatum was used to isolate synaptosomes, as it is a target region for Mn accumulation (Aschner et al., 2005). However, the striatum is a region of the brain less rich in NET and SERT relative to DAT. Whether or not these biogenic amine transporters play a role in Mn transport in noradrenergic or serotonergic areas of the brain remains unclear, however these brain regions are not typically involved in Mn neurotoxicity like the striatum. To definitively eliminate the potential role of NET and SERT in Mn accumulation in the brain, experiments using synaptosomes from more noradrenergic and serotonergic regions need to be conducted.

In those synaptosomes incubated in the absence of Mn, treatment with GBR12909 significantly increased Mn accumulation (Figure 3). Though unexpected, this observation may indicate upregulation of other potential Mn transport mechanisms found in the striatum such as DMT-1 (Roth and Garrick, 2003; Burdo et al., 1999), a transporter with an expanding role in regulating Mn concentrations (Erikson et al., 2004), voltage-gated calcium channels (Yokel and Crossgrove, 2004) or even the transferrin receptor (Connor et al., 2001; Malecki et al., 1999). Additionally, since Mn concentrations were not decreased by drug treatment under normal conditions, this supports data from a previous study that DAT may only be involved in Mn transport during toxic conditions (Erikson et al., 2005).

We used an iron deficient diet because it has been shown to facilitate Mn accumulation in the brain, especially in the basal ganglia (Kwik-Urbe et al., Erikson et al., 2002; 2004). However,

iron deficiency is known to alter dopamine transporter functioning (Erikson et al., 2000); so while we treated the ID rats with GBR identically to the rats fed the control diet, we did not see an effect of the drug on blocking the uptake of Mn into any brain region (data not shown). Iron (Fe) accumulated in a heterogeneous fashion across all brain regions. Those animals receiving the ID diet had significantly lower concentrations of Fe overall, but there was no statistically significant difference within each brain region when compared to control (Figure 6). In our previous studies, (Erikson et al., 2002) the dietary intervention was conducted for six weeks rather than the four weeks in this study. Thus, the degree of iron deficiency was less severe resulting in anemia but not significant Fe depletion within the brain regions which is known to result in Mn accumulation (Kwik-Uribe et al., 1999; Erikson et al., 2002). Importantly, we observed no effect of GBR12909 treatment on Fe accumulation which corroborates our previous study that showed that mice lacking a functioning DAT had altered accumulation of Mn but not Fe (Erikson et al., 2005).

As in previous studies (Erikson et al., 2002; 2004), Mn accumulated diversely in the brain and Mn concentrations were significantly higher in those animals receiving Mn supplementation in most brain regions (Figure 4). Treatment with GBR12909 significantly attenuated Mn accumulation in the globus pallidus, but not the caudate putamen of Mn-exposed (CNMn) rats (Figure 5). We found this surprising in that we expected the effects of treatment with GBR12909 to lie in a dopamine-rich brain region such as the caudate putamen (Erikson et al., 2005). However, it should be noted that these data are a collection of two separate animal experiments performed in the same manner (i.e., pharmacological and dietary treatments) and both experiments resulted in this finding that the effects of DAT blockade on inhibiting Mn accumulation are specifically unique to the globus pallidus.

We suggest two possible scenarios for why DAT blockade leads to decreased Mn accumulation in the globus pallidus (a GABA-ergic region) but not in the caudate putamen (a dopaminergic region). First, the effect of DAT blockade in the globus pallidus which has some dopaminergic input (Debeir et al., 2005; Gauthier et al., 1999) is directly leading to decreased transport of Mn into this region. While this is a plausible scenario, it is difficult to accept that blockade of the DAT located in the globus pallidus is leading to a 60% decrease in Mn concentration in supplemented animals. It could be that DAT blockade in this brain region causes an alteration in DMT-1 functioning thereby decreasing regional Mn transport, but this remains to be elucidated. A more likely scenario, albeit speculative, is that during Mn toxicity, the DAT facilitates Mn transport into striatal neurons (caudate putamen) and the Mn accumulates in the globus pallidus via axonal transport (Murayama et al., 2006; Slood and Gramsbergen, 1994). Thus, blockade of the DAT in the caudate putamen attenuates this accumulation of Mn in striatal neurons due to chronic Mn exposure ultimately causing decreased Mn concentrations in the globus pallidus. In a previous study using a DAT-KO mouse model, acute Mn exposure lead to a decrease in Mn accumulation in the caudate putamen (Erikson et al., 2005). A blockade of DAT in the caudate putamen might potentially lead to a buildup of Mn in that region under chronic exposure conditions as in this study.

In conclusion, these data suggest that during Mn toxicity, the DAT is involved in the facilitation of the specific accumulation of Mn into the globus pallidus. Whether the DAT is directly involved or indirectly is yet to be determined. Potentially, Mn may not be transported directly by DAT, but rather its transport may be affected by interaction(s) of the DAT protein with other putative Mn transporters, such as DMT-1 (Burdo et al., 1999), monocarboxylic acid transporters or voltage-gated calcium channels (Yokel and Crossgrove, 2004). Ongoing studies in our lab will help to further elucidate the specific role of DAT in Mn transport.

Acknowledgements

This research was supported by NIEHS Grant #ES013791-01.

References

- Aschner M, Erikson KM, Dorman DC. Manganese dosimetry: species differences and implications for neurotoxicity. *Crit Rev Tox* 2005;35:1–32.
- Autissier N, Rochette L, Dumas P, Beley A, Loireau A, Bralet J. Dopamine and norepinephrine turnover in various regions of the rat brain after chronic manganese chloride administration. *Toxicology* 1982;24:175–182. [PubMed: 7135412]
- Borowsky RD, Hoffman BJ. Neurotransmitter transporters: molecular biology, function, and regulation. *Int Rev Neurobiol* 1995;38:139–199. [PubMed: 8537200]
- Burdo JR, Martin J, Menzies SL, Dolan KG, Romano MA, Fletcher RJ, Garrick MD, Garrick LM, Connor JR. Cellular distribution of iron in the brain of the Belgrade rat. *Neuroscience* 1999;93:1189–1196. [PubMed: 10473284]
- Connor J, Menzies S, Burdo J, Boyer P. Iron and iron management proteins in neurobiology. *Pediatr Neurol* 2001;25:118–129. [PubMed: 11551742]
- Debeir T, Ginestet L, Francois C, Laurens S, Martel JC, Chopin P, Marien M, Colpaert F, Raisman-Vozari R. Effect of intrastriatal 6-OHDA lesion on dopaminergic innervation of the rat cortex and globus pallidus. *Exp Neurol* 2005;93:444–454. [PubMed: 15869947]
- Erikson KM, Aschner M. Increased manganese uptake by primary astrocyte cultures with altered iron status is mediated primarily by divalent metal transporter. *Neurotoxicology* 2006;27:125–130. [PubMed: 16140386]
- Erikson KM, John CE, Jones SR, Aschner M. Manganese accumulation in striatum of mice exposed to toxic doses is dependent upon a functional dopamine transporter. *Environ Tox Pharm* 2005;20:390–394.
- Erikson KM, Syversen T, Steinnes E, Aschner M. Globus pallidus: a target brain region for divalent metal accumulation associated with dietary iron deficiency. *J NutrBiochem* 2004;15:335–341.
- Erikson KM, Shihabi ZK, Aschner JL, Aschner M. Manganese accumulates in iron-deficient rat brain regions in a heterogeneous fashion and is associated with neurochemical alterations. *Biolog Trace Elem Res* 2002;87:143–156.
- Erikson KM, Jones BC, Beard JL. Iron deficiency alters dopamine transporter functioning in rat striatum. *J Nutr* 2000;130:2831–2837. [PubMed: 11053528]
- Gauthier J, Parent M, Levesque M, Parent A. The axonal arborization of single nigrostriatal neurons in rats. *Brain Res* 1999;834:228–232. [PubMed: 10407122]
- Hurley, LS.; Keen, CL. Manganese. In: Underwood, E.; Mertz, W., editors. *Trace Elements in Human Health and Animal Nutrition*. Academic Press; New York, NY: 1987. p. 185-223.
- Ingersoll RT, Montgomery EB Jr, Aposhian HV. Central nervous system toxicity of manganese. II: Cocaine or reserpine inhibit manganese concentration in the rat brain. *Neurotoxicology* 1999;20:467–476. [PubMed: 10385905]
- Kwik-Urbe CL, Golub MS, Keen CL. Chronic marginal iron intakes during early development in mice alter brain iron concentrations and behavior despite postnatal iron supplementation. *J Nutr* 1999;130:2040–2048. [PubMed: 10917923]
- Malecki EA, Devenyi AG, Beard JL, Connor JR. Existing and emerging mechanisms for transport of iron and manganese to the brain. *J Neurosci Res* 1999;56:113–122. [PubMed: 10777372]
- Murayama Y, Weber B, Saleem KS, Augath M, Logothetis NK. Tracing neural circuits in vivo with Mn-enhanced MRI. *Mag Res Imag* 2006;24:349–358.
- Pal PK, Samii A, Calne DB. Manganese neurotoxicity: a review of clinical features, imaging and pathology. *Neurotoxicology* 1999;20:227–238. [PubMed: 10385886]
- Petzinger GM, Fisher B, Hogg E, Abernathy A, Arevalo P, Nixon K, Jakowec MW. Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned squirrel monkey (*Saimiri sciureus*): changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins. *J Neurosci Res* 2006;83:332–347. [PubMed: 16385585]
- Reaney SH, Smith DR. Manganese oxidation state mediates toxicity in PC12 cells. *Tox App Pharm* 2005;205:271–281.
- Ritz MC, Boja JW, Grigoriadis D, Zaczek R, Carroll FI, Lewis AH, Kuhar MJ. 3H-WIN 35, 065–2: a ligand for cocaine receptors in striatum. *J Neurochem* 1990;55:1556–1562. [PubMed: 2120386]

- Roth JA, Garrick MD. Iron interactions and other biological reactions mediating the physiological and toxic actions of manganese. *Biochem Physiol* 2003;66:1–13.
- Sloot WN, Gramsbergen JBP. Axonal transport of manganese and its relevance to selective neurotoxicity in the rat basal ganglia. *Brain Res* 1994;657:124–132. [PubMed: 7820609]
- Verity MA. Manganese neurotoxicity: a mechanistic hypothesis. *Neurotoxicology* 1999;20:489–497. [PubMed: 10385907]
- Yang W, Tiffany-Castiglioni E. The bipyridyl herbicide paraquat produces oxidative stress-mediated toxicity in human neuroblastoma SH-SY5Y cells: relevance to the dopaminergic pathogenesis. *J Tox Environ Health* 2005;68:1939–1961.
- Yokel RA, Crossgrove JS. Manganese toxicokinetics at the blood-brain barrier. *Res Rep Health Eff Inst* 2004;199:7–58. [PubMed: 15043400]

Figure 1.

Experimental design of in vivo studies. Weanling male Sprague-Dawley rats were randomly placed into one of four dietary treatment groups: control (CN), iron-deficient (ID), control with Mn supplementation (via the drinking water; 1g Mn/L) (CNMn), and ID with Mn supplementation (IDMn). Two independent experiments with two separate sets of animals were conducted ($n = 24$ for each experiment; $n = 48$ total). Within each dietary group, half of the rats received intraperitoneal injections of GBR12909, 1 mg/kg (ED-50), three times per week while the other half received saline injections of equal volume. Dietary and pharmacological intervention lasted for four weeks.

Figure 2.

Mean uptake of ^3H -dopamine is shown for striatal synaptosomes incubated in the absence (gray) or presence (white) of biogenic amine transporter inhibitors for dopamine (DA), norepinephrine (NE) or serotonin (5HT) at the ED50 dose (1 μM GBR12909; 100 μM desipramine; 10 μM fluoxetine) for 5 minutes.

Figure 3.

Manganese concentration [$\mu\text{g/L}$] is shown for striatal synaptosomes incubated in the absence or presence of 0.5 mM manganese for 5 minutes. Synaptosomes either received no treatment (gray), 1 μM GBR12909 (dotted), 100 μM desipramine (striped), or 10 μM fluoxetine (white). The mean concentration is shown with SEM. * p-value < 0.001

Figure 4.

Manganese concentration [nmol/g tissue] is shown for all brain regions: globus pallidus (GP); caudate putamen (CP); hippocampus (HC); substantia nigra (SN); and cerebellum (CB). Diets were CN (gray), CNMn (dotted), ID (striped), and IDMn (white). Mn supplementation led to a significant increase in brain regional Mn concentrations as indicated by the asterisk. The mean concentration is shown with SEM. * p-value < 0.05

Figure 5.

Manganese concentrations [nmol/g tissue] are shown for CN and CNMn groups with and without 1 mg/kg GBR for three representative brain regions: globus pallidus (GP), caudate putamen (CP), and hippocampus (HC). Diets were CN (gray), CNMn (dotted), ID (striped), and IDMn (white). The mean concentration is shown with SEM. * p-value < 0.001; † p-value = 0.07

Figure 6.

Iron concentration [nmol/g tissue] is shown for all brain regions: globus pallidus (GP); caudate putamen (CP); hippocampus (HC); substantia nigra (SN); and cerebellum (CB). Diets were CN (gray), CNMn (dotted), ID (striped), and IDMn (white). The mean concentration is shown with SEM. † p-value = 0.13

Table 1

Mean body weight and hematocrit. Mean body weight (grams) and hematocrit are given for each treatment group $\pm$ SD. Means in a column not sharing a superscript are significantly different ($p < 0.05$).

Group	Body weight (g)	Hematocrit
CN	196.9 $\pm$ 24.2 ^a	0.47 $\pm$ 0.02 ^a
CN with GBR treatment	201.1 $\pm$ 25.1 ^a	0.43 $\pm$ 0.08 ^a
CNMn	192.0 $\pm$ 23.3 ^a	0.43 $\pm$ 0.04 ^a
CNMn with GBR treatment	179.5 $\pm$ 1.83 ^a	0.42 $\pm$ 0.04 ^a
ID	168.1 $\pm$ 13.0 ^b	0.15 $\pm$ 0.05 ^b
ID with GBR treatment	148.2 $\pm$ 6.52 ^b	0.15 $\pm$ 0.08 ^b
IDMn	116.8 $\pm$ 12.7 ^b	0.19 $\pm$ 0.05 ^b
IDMn with GBR treatment	109.5 $\pm$ 7.27 ^b	0.16 $\pm$ 0.05 ^b